Damora Therapeutics, Inc.
DMRANasdaq
$31.48
↑ +4.1%Jul 17 close · end-of-day
Price
1Y↑ +799.4%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$1.1B
Enterprise Value
$546.8M
P/E
6.0
P/S
—
P/B
2.1
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$235.1M
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-46.0%
ROIC
—
Debt / Equity
—
Net Cash
$532.9M
Return 1Y
+762.5%
Company profile
Galecto, Inc. develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the. treatment of myelofibrosis. GB0139, an inhaled. inhibitor of galectin-3 that is in. Phase IIb clinical trials for severe fibrotic lung diseases.
- CEO
- Hans T. Schambye
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 40
- Headquarters
- Massachusetts
- Website
- galecto.com
Management & directors
- Winslow GarrettGeneral Counsel
- Jarrett JenniferSee Remarks
- Hewes L. BeckerChief Medical Officer
- Sattarzadeh SherwinChief Operating Officer
- Firmani LoriChief Financial Officer
- Schambye Hans T.Chief Executive Officer
Roles derived from SEC Form 4 filings.
Earnings
DMRA Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue——
Diluted EPS-$0.62↓ -67.7%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$33.6M | -$52.2M | -$61.2M | -$39.9M | -$22.3M | -$210.9M |
| Net income | -$34.8M | -$51.8M | -$61.6M | -$38.3M | -$21.4M | -$209.8M |
| Diluted EPS | — | -$2.05 | -$2.43 | -$36.08 | -$18.53 | $3.98 |
| Operating cash flow | -$38.2M | -$52.3M | -$42.9M | -$36.9M | -$18.6M | -$6.7M |
| Free cash flow | — | -$52.5M | -$43.1M | — | — | — |
| Gross margin | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$5.6M | -$3.8M | -$7.1M | -$2.6M | -$3.4M | -$3.2M | -$201.7M | -$30.8M |
| Net income | -$5.3M | -$3.9M | -$6.7M | -$2.5M | -$3.4M | -$3.1M | -$200.7M | -$27.8M |
| Diluted EPS | -$4.92 | -$3.39 | -$5.17 | -$1.92 | -$2.60 | -$2.36 | $10.86 | -$0.62 |
| Operating cash flow | -$4.1M | -$3.7M | -$4.9M | -$2.4M | -$2.2M | -$2.6M | $566,000.00 | -$20.6M |
| Free cash flow | — | — | — | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — | — | — |
Company news
May 30, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-07-06 | Winslow Garrett· General Counsel | Sale | 245 | $29.98 | $7,345.10 | filing |
| 2026-07-03 | Winslow Garrett· General Counsel | Option exercise | 680 | — | — | filing |
| 2026-03-30 | Jarrett Jennifer· See Remarks | Award | 500,000 | $0.00 | $0.00 | filing |
| 2026-02-09 | Fairmount Funds Management LLC | Option exercise | 2,904,000 | $0.00 | $0.00 | filing |
| 2026-02-09 | Bruno Julianne | Option exercise | 129,000 | $0.00 | $0.00 | filing |
| 2026-02-09 | Fairmount Funds Management LLC | Option exercise | 5,809,000 | $0.00 | $0.00 | filing |
| 2026-01-05 | Sattarzadeh Sherwin· Chief Operating Officer | Award | 190,376 | $0.00 | $0.00 | filing |
| 2026-01-05 | Hewes L. Becker· Chief Medical Officer | Award | 264,629 | $0.00 | $0.00 | filing |
| 2026-01-02 | Schambye Hans T.· Chief Executive Officer | Sale | 700 | $21.38 | $14,966.00 | filing |
| 2026-01-02 | Winslow Garrett· General Counsel | Sale | 255 | $21.38 | $5,451.90 | filing |
| 2026-01-02 | Firmani Lori· Chief Financial Officer | Sale | 135 | $21.41 | $2,890.35 | filing |
| 2026-01-02 | Winslow Garrett· General Counsel | Option exercise | 680 | — | — | filing |
| 2026-01-02 | Schambye Hans T.· Chief Executive Officer | Option exercise | 1,360 | — | — | filing |
| 2026-01-02 | Firmani Lori· Chief Financial Officer | Option exercise | 374 | — | — | filing |
| 2025-07-03 | Schambye Hans T.· Chief Executive Officer | Sale | 735 | $3.38 | $2,484.30 | filing |
| 2025-07-03 | Winslow Garrett· General Counsel | Sale | 260 | $3.39 | $881.40 | filing |
| 2025-07-03 | Firmani Lori· Interim CFO | Sale | 147 | $3.39 | $498.33 | filing |
| 2025-07-03 | Schambye Hans T.· Chief Executive Officer | Option exercise | 1,360 | — | — | filing |
| 2025-07-03 | Winslow Garrett· General Counsel | Option exercise | 680 | — | — | filing |
| 2025-07-03 | Firmani Lori· Interim CFO | Option exercise | 374 | — | — | filing |
Latest 20 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.